Trials / Completed
CompletedNCT00536237
MK0524A Phase IIb Study (0524A-011)(COMPLETED)
Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on Niacin-Induced Flushing in Lipid Clinic Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Part A: This study will determine that MK0524 is well tolerated and does not effect lipids and blood glucose when given alone. Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids and blood glucose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Comparator: niacin / Duration of Treatment: 17 Weeks | |
| DRUG | MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks | |
| DRUG | Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2005-02-01
- Completion
- 2006-12-01
- First posted
- 2007-09-27
- Last updated
- 2015-08-25
Source: ClinicalTrials.gov record NCT00536237. Inclusion in this directory is not an endorsement.